SS18-SSX2 and the mitochondrial apoptosis pathway in mouse and human synovial sarcomas
Open Access
- 16 July 2012
- journal article
- research article
- Published by Springer Science and Business Media LLC in Oncogene
- Vol. 32 (18), 2365-2371
- https://doi.org/10.1038/onc.2012.247
Abstract
Synovial sarcoma is a deadly malignancy with limited sensitivity to traditional cytotoxic chemotherapy. SS18-SSX fusion oncogene expression characterizes human synovial sarcomas and drives oncogenesis in a mouse model. Elevated expression of BCL2 is considered a consistent feature of the synovial sarcoma expression profile. Our objective was to evaluate the expression of apoptotic pathway members in synovial sarcomas and interrogate the impact of modulating SS18-SSX expression on this pathway. We show in human and murine synovial sarcoma cells that SS18-SSX increases BCL2 expression, but represses other anti-apoptotic genes, including MCL1 and BCL2A1. This repression is achieved by directly suppressing expression via binding through activating transcription factor 2 (ATF2) to the cyclic adenosine monophosphate (AMP) response element (CRE) in the promoters of these genes and recruiting TLE1/Groucho. The suppression of these two anti-apoptotic pathways silences the typical routes by which other tumors evade BH3-domain peptidomimetic pharmacotherapy. We show that mouse and human synovial sarcoma cells are sensitive in vitro to ABT-263, a BH3-peptidomimetic, much more than the other tested cancer cell lines. ABT-263 also enhances the sensitivity of these cells to doxorubicin, a traditional cytotoxic chemotherapy used for synovial sarcoma. We also demonstrate the capacity of ABT-263 to stunt synovial sarcomagenesis in vivo in a genetic mouse model. These data recommend pursuit of BH3-peptidomimetic pharmacotherapy in human synovial sarcomas.Keywords
This publication has 22 references indexed in Scilit:
- Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activityThe Lancet Oncology, 2010
- Gene Expression Profiling of Synovial Sarcoma: Distinct Signature of Poorly Differentiated TypeThe American Journal of Surgical Pathology, 2010
- EGR1 reactivation by histone deacetylase inhibitors promotes synovial sarcoma cell death through the PTEN tumor suppressorOncogene, 2010
- Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1Blood, 2010
- TLE1 is a robust diagnostic biomarker for synovial sarcomas and correlates with t(X;18): Analysis of 319 casesEuropean Journal Of Cancer, 2010
- A CreER-Based Random Induction Strategy for Modeling Translocation-Associated Sarcomas in MiceCancer Research, 2009
- ABT-263: A Potent and Orally Bioavailable Bcl-2 Family InhibitorCancer Research, 2008
- Extent, relationship and prognostic significance of apoptosis and cell proliferation in synovial sarcomaEuropean Journal of Cancer Prevention, 2006
- G3139 antisense oligonucleotide directed against antiapoptotic Bcl‐2 enhances doxorubicin cytotoxicity in the FU‐SY‐1 synovial sarcoma cell lineJournal of Orthopaedic Research, 2006
- Induced DNA recombination by Cre recombinase protein transductiongenesis, 2002